Preview

Научно-практическая ревматология

Расширенный поиск

Полимиозит/дерматомиозит: дифференциальная диагностика

https://doi.org/10.14412/1995-4484-2016-191-198

Полный текст:

Аннотация

В лекции рассматривается проблема редких системных заболеваний соединительной ткани – идиопатических воспалительных миопатий (ИВМ). Подчеркивается клинико-иммунологическая неоднородность их подтипов, определяющая терапевтическую тактику и прогноз. Представлены диагностические критерии ИВМ. Предлагается алгоритм дифференциальной диагностики, который базируется на исключении фенотипически сходных форм миопатий различного генеза. 

Об авторе

О. А. Антелава
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия

Институт профессионального образования

кафедра ревматологии 

канд. мед. наук



Список литературы

1. Plotz PH, Dalakas M, Leff RL, et al. Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Intern Med. 1989;111:143. doi: 10.7326/0003-4819-111-2-143

2. Dalakas M. Mechanisms of disease:signaling pathways and immunobyology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2(4):219-27. doi: 10.1038/ncprheum0140

3. Sarkar K, Miller FW. Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity. 2004 Jun;37(4):291-4. doi: 10.1080/08916930410001710839

4. Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskel Dis. 2011;3:315-24. doi: 10.1177/1759720X11415306

5. Mastaglia FL. Inflammatory muscle diseases. Neurol India. 2008;56:263-70. doi: 10.4103/0028-3886.43444

6. Van der Kooi AJ, de Visser M. Idiopathic inflammatory myopathies. Handb Clin Neurol. 2014;119:495-512. doi: 10.1016/B978-0-7020-4086-3.00032-1

7. Раденска-Лоповок СГ. Основные разновидности воспалительных миопатий: морфологическая дифференциальная диагностика. Нервно-мышечные болезни. 2011;(1):5-8 [Radenska-Lopovok SG. The main varieties of inflammatory myopathies: morphological differential diagnosis. Nervno-Myshechnye Bolezni. 2011;(1):5-8 (In Russ.)].

8. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17:194-200. doi: 10.1016/j.nmd.2006.10.007

9. Lunberg I, Ulfgren A-K, Nyberg P, et al. Cynokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865-74. doi: 10.1002/art.1780400514

10. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg. 2009;Psychiat 80:1186-93.

11. Насонов ЕЛ, Штутман ВЗ, Саложин КВ и др. Клинико-иммунологическая гетерогенность идиопатических воспалительных миопатий. Клиническая медицина. 1995;(2):3-8 [Nasonov EL, Shtutman VZ, Salozhin KV, et al. Clinical and immunological heterogeneity of idiopathic inflammatory myopathies. Klinicheskaya Meditsina. 1995;(2):3-8 (In Russ.)].

12. Lega JC, Cottin V, Fabien N, et al. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37(5):1000-9. doi: 10.3899/jrheum.090652

13. Ghirardello A, Zampieri S, Tarricone E, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006;39:217-21. doi: 10.1080/08916930600622645

14. Ghirardello A, Zampieri S, Iaccarino L, et al. Anti-MI-2 antibodies. Autoimmunity. 2005;38:79-83 doi: 10.1080/08916930400022681

15. Zampieri S, Ghirardello A, Iaccarino L, et al. Anti-JO-1 antibodies. Autoimmunity. 2005;38:73-8. doi: 10.1080/08916930400022640

16. Mahler M, Raijmakers R, Dä hnrich C, et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther. 2005;7(3):R704-13. doi: 10.1186/ar1729

17. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis) Presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24:959-66. doi: 10.1016/0190-9622(91)70153-S

18. Sontheimer RD. A portable digital microphotography unit for rapid documentation of periungualnailfold capillary changes in autoimmune connective tissue diseases. J Rheumatol. 2004 Mar;31(3):539-44.

19. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung diseasewith anti-MDA5 antibody-positive der￾matomyositis. Rheumatology (Oxford). 2012 May 15.

20. Ghazi E, Sontheimer RD, Werth VP. The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol. 2013 Jan-Feb;31(1):128- 34. Epub 2012 Nov 22.

21. Антелава ОА. Паранеопластический миозит. Особенности дебюта, клинической картины, течения, стероид-респонсивности. Научно-практическая ревматология. 2013;51(2):181-5 [Antelava OA. The specific features of the onset, clinical picture, steroid responsiveness of paraneoplastic myositis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):181-5 (In Russ.)]. doi: 10.14412/1995-4484-2013-647

22. Christopher-Stine L, Casciola-Rosen LA, Hong,G, et al. A novel autoantibody recognizing 200-kd and100 kd proteins is associated with an immune mediated ecrotizing myopathy. Arthritis Rheum. 2010;62:2757-66. doi: 10.1002/art.27572

23. So MW, Koo BS, Kim YGC, et al. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and olymyositis. J Rheumatol. 2011;38(11):2432-5. doi: 10.3899/jrheum.110320

24. Антелава ОА, Тарасова ГМ, Сажина ЕГ и др. Антисинтетазный синдром — наиболее тяжелый подтип полимиозита/дерматомиозита (описание случаев). Современная ревматология. 2009;3(4):54-8 [Antelava OA, Tarasova GM, Sazhina EG, et al. Antisynthetase syndrome is the most severe subtype of polymyositis/dermatomyositis: description of cases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2009;3(4):54-8 (In Russ.)]. doi: 10.14412/1996-7012-2009-574

25. Ананьева ЛП, Волков АВ, Смирнов АВ, Антелава ОА. Поражение органов дыхания при системных заболеваниях соеди- нительной ткани. В кн.: Чучалин АГ, редактор. Респираторная медицина: Руководство. Москва: ГЭОТАР-Медиа; 2007. Т. 2. С. 251-68 [Anan’eva LP, Volkov AV, Smirnov AV, Antelava OA. The defeat of the respiratory system in systemic diseases of con￾nective tissue. In: Chuchalin AG, editor. Respiratornaya meditsina: Rukovodstvo [Respiratory Medicine: A Guide]. Moscow: GEOTAR-Media; 2007. Vol. 2. P. 251-68].

26. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633-8. doi: 10.1097/BOR.0b013e32833f1970

27. Антелава ОА, Балабанова РМ, Сажина ЕГ и др. Особенности дебюта и течения антисинтетазного синдрома как наиболее тяжелого подтипа полимиозита/дерматомиозита. Русский медицинский журнал. 2009;21:1443 [Antelava OA, Balabanova RM, Sazhina EG, et al. Features debut and course antisintetaznogo syndrome as the most severe subtype of polymyositis/dermatomyositis. Russkii Meditsinskii Zhurnal. 2009;21:1443 (In Russ.)].

28. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome.Curr Rheumatol Rep. 2011;13:175-81. doi: 10.1007/s11926- 011-0176-8

29. Антелава ОА, Бондаренко ИБ, Хитров АН, Насонов ЕЛ. Поражение дыхательной системы при полимиозите/дерматоми- озите. Русский медицинский журнал. 2008;34(24):1633-7 [Antelava OA, Bondarenko IB, Khitrov AN, Nasonov EL. The defeat of the respiratory system with polymyositis/dermatomyositis. Russkii Meditsinskii Zhurnal. 2008;34(24):1633-7 (In Russ.)].

30. Mileti LM, Strek ME, Niewold TB, et al. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009;15(5):254-5. doi: 10.1097/RHU.0b013e3181b0e910

31. Hervier B, Wallaert B, Hachulla E, et al. Clinical manifestations of antisynthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49(5):972-6. doi: 10.1093/rheumatology/kep455

32. Handa T, Nagai S, Kawabata D, et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med. 2005;44(4):319-25. doi: 10.2169/internalmedicine.44.319

33. Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti￾PL-12 autoantibody: cohort study and review of the literature. Chest. 2009;135(6):1550-6. doi: 10.1378/chest.08-2233

34. Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34(5):1012-8.

35. Arnett FC, Targoff IN, Mimori T, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39:1507-18. doi: 10.1002/art.1780390910

36. Hengstman GJD, Brouwer R, Vree Egberts WTM, et al. Clinical and serological characteristics of 125 Dutch myositis patients; myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol. 2002;249:69- 75. doi: 10.1007/PL00007850

37. Hirakata M, Nakamura K, Fuji J, et al. Clinical and immunogenetic features of anti-SRP autoantibodies in Japanese patients. Arthritis Rheum. 1995;38:S321.

38. Targoff IN, Johnson AE, Miller FW. Antibody to signal recogni￾tion particle. Arthritis Rheum. 1990;33:1361-70. doi: 10.1002/art.1780330908

39. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40(4):581-6. doi: 10.1002/ana.410400407

40. Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol. 2000;2(1):7-12. doi: 10.1007/s11940-000-0019-9

41. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve. 2001;24:1526-34. doi: 10.1002/mus.1178

42. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79(9):1056-60. doi: 10.1136/jnnp.2007.138891

43. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302-4. doi: 10.1212/WNL.45.7.1302

44. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112(Pt 3):727-47. doi: 10.1093/brain/112.3.727

45. Rodriguez Cruz PM, Needham M, Hollingsworth P, et al. Sleep dis￾ordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. Neuromuscul Disord. 2014;24:1036-41. doi: 10.1016/j.nmd.2014.08.003

46. Della Marca G, Sancricca C, Losurdo A, et al. Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis. Clin Neurophysiol. 2013;124:1615-21. doi: 10.1016/j.clinph.2013.03.002

47. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167-75. doi: 10.1093/brain/awr217

48. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-7. doi: 10.1056/NEJM197502202920807

49. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7. doi: 10.1056/NEJM197502132920706

50. Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9:527-35. doi: 10.1097/00002281-199711000-00008

51. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004 May;14(5):337-45. doi: 10.1016/j.nmd.2004.02.006

52. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705-13. doi: 10.1002/ana.410380504

53. Selva-O’Callaghan A, Fonollosa-Pla V, Trallero-Araguas E, et al. Nailfold capillary microscopy in adults withinflammatory myopathy. Sem Arthritis Rheum. 2010a;39:398-404. doi: 10.1016/j.semarthrit.2008.09.003

54. Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53-9. doi: 10.1136/thx.2006.069237

55. Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and otherproximalmyopathies. Thorax. 1983;38(8):616-23. doi: 10.1136/thx.38.8.616

56. Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford). 2006;45 Suppl 4: iv18-21. doi: 10.1093/rheumatology/kel311

57. Costa AF, Di Primio GA, Schweitzer ME. Magnetic resonance imaging of muscle disease: A pattern-based approach. Muscle Nerve. 2012;46:465-81. doi: 10.1002/mus.23370

58. Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153-61. doi: 10.1093/rheumatology/ker001

59. Tasca G, Monforte M, De Fino C, et al. MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. 2015;52(6):956-62. doi: 10.1002/mus.24661

60. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol. 2002;29:1897-906.

61. Антелава ОА, Насонов ЕЛ. Современные методы оценки активности и повреждения при идиопатических воспалительных миопатиях. Научно-практическая ревматология. 2007;45(1):59-62 [Antelava OA, Nasonov EL. Modern methods of evaluation activity and damage in idiopathic inflammatory myopathies. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(1):59-62 (In Russ.)].


Для цитирования:


Антелава О.А. Полимиозит/дерматомиозит: дифференциальная диагностика. Научно-практическая ревматология. 2016;54(2):191-198. https://doi.org/10.14412/1995-4484-2016-191-198

For citation:


Antelava O.A. POLYMYOSITIS/DERMATOMIOSITIS: DIFFERENTIAL DIAGNOSIS. Rheumatology Science and Practice. 2016;54(2):191-198. (In Russ.) https://doi.org/10.14412/1995-4484-2016-191-198

Просмотров: 606


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)